Welcome to our dedicated page for Modular Medical SEC filings (Ticker: MODD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Modular Medical's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Modular Medical's regulatory disclosures and financial reporting.
Modular Medical, Inc. reported that its Chief Operating Officer, Kevin Schmid, received a grant of options to purchase 4,674 shares of common stock. The options have an exercise price of $3.46 per share and expire on May 14, 2036.
According to the grant terms, one-third of the option shares will vest on May 14, 2027, with the remaining shares vesting in equal monthly installments of 1/36th thereafter. Following this grant, Schmid holds 4,674 options of this derivative security directly.
Modular Medical, Inc. ownership update: Solas Capital Management, LLC and portfolio manager Frederick Tucker Golden report beneficial ownership of 464,850 shares of Common Stock, representing approximately 9.6% of the class. The position comprises 288,095 shares of Common Stock and 176,755 shares issuable upon exercise of warrants, based on 4,660,360 shares outstanding as of March 31, 2026. The filing states shared voting and dispositive power over all 464,850 shares and disclaims beneficial ownership by the underlying funds under Rule 13d-4.
Modular Medical, Inc. reports that 683 Capital Partners, LP (through its manager 683 Capital Management, LLC and Managing Member Ari Zweiman) beneficially owned 125,001 common shares and warrants exercisable for 134,239 shares. The filing states this position represents approximately 4.67% of the outstanding common stock, based on 5,411,177 shares outstanding as of April 21, 2026, with the 4.67% figure given as of May 15, 2026.
Modular Medical, Inc. ownership update: Bard Associates, Inc. reports beneficial ownership of 102,831 shares of Common Stock as of 05/13/2026. The filing states this represents 0.1% of the class, with 3,716 shares sole voting power and 99,115 shares subject to shared dispositive power.
AWM Investment Company, Inc. reports beneficial ownership of 540,576 shares of Modular Medical, Inc., representing 9.99% of the class. AWM serves as investment adviser to four affiliated funds and discloses sole voting and dispositive power over these shares. The filing also describes pre-funded warrants and other warrants exercisable subject to a 9.99% ownership cap.
Modular Medical, Inc. filed a shelf registration to offer up to $150,000,000 of securities to be issued from time to time, including common stock, preferred stock, debt securities, warrants and units, with specific offerings to be described in prospectus supplements. The company also established a sales agreement with Maxim Group LLC permitting at-the-market sales of up to $100,000,000 of common stock.
The prospectus discloses recent financing activity including a March 2026 registered direct offering that raised approximately $12.0 million, an April 2026 registered direct offering that raised approximately $3.375 million, a December 2025 public offering that raised approximately $4.7 million (plus a $0.7 million overallotment), a secured $350,000 credit note from the CEO, a 1-for-30 reverse stock split effective March 31, 2026, and FDA clearance received April 9, 2026 for the Pivot product with commercialization planned in the quarter ending June 30, 2026.
Modular Medical, Inc. entered into a Placement Agency Agreement for a registered direct offering of 750,000 shares of common stock at $4.50 per share, for expected gross proceeds of about $3.375 million before fees and expenses.
Maxim Group LLC will act as sole placement agent, earning a 7% cash fee on gross proceeds and expense reimbursement up to $75,000. The offering is made under an effective Form S-3 shelf registration and is expected to close on or about April 21, 2026, subject to customary conditions.
Company directors and executive officers agreed to 90-day lock-up restrictions, and the Company agreed to limit additional equity issuances for 45 days after closing, subject to specified exceptions.
Modular Medical, Inc. is offering 750,000 shares of common stock at $4.50 per share. The prospectus supplement states the offering price was negotiated with the placement agent and investors and delivery is expected on or about April 21, 2026.
The company expects net proceeds of approximately $2.9 million, which it intends to use for working capital, capital expenditures and general corporate purposes. The filing discloses substantial doubt about the company’s ability to continue as a going concern without additional financing and notes pivot product FDA clearance and a planned commercial launch.
Modular Medical, Inc. has regained compliance with the Nasdaq Capital Market’s minimum bid price continued listing requirement. Nasdaq notified the company after its common stock maintained a closing bid above the $1.00 minimum for 10 consecutive trading days through April 14, 2026.
With compliance restored under Nasdaq Listing Rule 5550(a)(2), Nasdaq considers the matter closed, meaning the company’s common stock can continue trading on the Nasdaq Capital Market under the symbol MODD without an active bid-price deficiency issue.